Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer
Clinical trial NCT02390427 · COMPLETED
Trial details
- NCT number
- NCT02390427
- Sponsor
- Otto Metzger, MD
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2015-04-20
- Primary completion
- 2022-12-01
- Enrollment
- 68
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.